Drug:
Reaction: GENERAL PHYSICAL HEALTH DETERIORATION
20250101 - 20251231
No. 1801 - 1900
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1801 | 24858384 |
CA |
61 | 1 |
Fall, Hypotension, Lethargy, Adverse event, Dehydration, Decreased appetite, General physical health deterioration, |
||||
CLOZAPINE, MIRTAZAPINE, MEMANTINE, MEMANTINE HYDROCHLORIDE, CLONAZEPAM, ARIPIPRAZOLE, |
||||
| 1802 | 24858553 |
US |
1 | |
General physical health deterioration, Therapy interrupted, |
||||
CLOZAPINE, |
||||
| 1803 | 24847353 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1804 | 24847390 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1805 | 24847416 |
CA |
11 | 1 |
Haematochezia, Vomiting, Diarrhoea, Gastrointestinal inflammation, General physical health deterioration, |
||||
INFLIXIMAB, |
||||
| 1806 | 24847456 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1807 | 24847478 |
US |
1 | |
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1808 | 24847904 |
US |
50 | |
Road traffic accident, Injury, General physical health deterioration, Rib fracture, Pain, Malnutrition, Acute kidney injury, Skin laceration, Acute respiratory failure, Cardiac failure, Hypophagia, Anxiety, Depression, Chronic obstructive pulmonary disease, |
||||
DAPAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN, |
||||
| 1809 | 24848002 |
US |
83 | 1 |
Thoracic vertebral fracture, Fall, General physical health deterioration, Metastasis, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 1810 | 24848065 |
IN |
73 | 2 |
Dementia Alzheimer^s type, Urinary tract infection, Viral infection, Decubitus ulcer, Speech disorder, Immobile, Blood sodium abnormal, General physical health deterioration, |
||||
TOCILIZUMAB, |
||||
| 1811 | 24848193 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1812 | 24848346 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1813 | 24848660 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1814 | 24848718 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1815 | 24849027 |
DE |
79 | 2 |
Nephrolithiasis, Chronic kidney disease, Blood creatinine increased, General physical health deterioration, Asthenia, Glomerular filtration rate decreased, Nephrolithiasis, Leukopenia, Renal impairment, Thrombocytopenia, Acute kidney injury, Osteoarthritis, Hyponatraemia, Osteoarthritis, Cardiac failure congestive, Vomiting, Nausea, Neutropenia, Concomitant disease aggravated, Atrial fibrillation, Electrocardiogram QT prolonged, Anaemia, Urinary retention, Cardiac failure, Hypertension, Blood glucose increased, Eastern Cooperative Oncology Group performance status worsened, Bronchitis, Cystitis, Infection, Blood thyroid stimulating hormone increased, C-reactive protein increased, Pleural effusion, Urinary tract infection, Blood pressure increased, Oedema peripheral, Dry skin, Dyspnoea, Product use in unapproved indication, |
||||
LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CALCIUM, DAPAGLIFLOZIN, DAPAGLIFLOZIN, |
||||
| 1816 | 24849148 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1817 | 24850138 |
DE |
69 | 1 |
General physical health deterioration, Vascular device infection, |
||||
| 1818 | 24850274 |
IT |
63 | 1 |
Syncope, Electrocardiogram ST-T segment abnormal, Diarrhoea, General physical health deterioration, Treatment noncompliance, Drug intolerance, Off label use, |
||||
OXALIPLATIN, OXALIPLATIN, TUCATINIB, TUCATINIB, LEVOLEUCOVORIN, LEVOLEUCOVORIN CALCIUM, FLUOROURACIL, FLUOROURACIL, TRASTUZUMAB, ENOXAPARIN SODIUM, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 1819 | 24850928 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1820 | 24850944 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1821 | 24850951 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1822 | 24851002 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1823 | 24851007 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1824 | 24851472 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1825 | 24851483 |
CO |
2 | |
Death, Dyspnoea exertional, Breast enlargement, Mass, Erythema, Skin disorder, Nipple disorder, Breast ulceration, Purulent discharge, Spinal disorder, Musculoskeletal discomfort, Contusion, Spinal cord contusion, Pleural effusion, Lumbar vertebral fracture, Traumatic spinal cord compression, Traumatic arthropathy, Somnolence, Haematocrit abnormal, Haemoglobin abnormal, Blood potassium abnormal, Fall, Lung opacity, Cardiac disorder, Hilar lymphadenopathy, Atelectasis, Neutrophilia, Oxygen saturation abnormal, Insomnia, Feeling abnormal, Body fat disorder, Skin hypertrophy, Oedema peripheral, Body mass index decreased, White blood cell disorder, Muscle atrophy, Mucosal discolouration, Breast induration, Hemiparesis, Hypoventilation, Orthopnoea, Dyspnoea paroxysmal nocturnal, Hypertension, Oral disorder, Induration, Breast discharge, Pulmonary mass, Pleural thickening, Bloody discharge, General physical health deterioration, Neutrophil count abnormal, Blood creatinine abnormal, Prothrombin time abnormal, Activated partial thromboplastin time abnormal, White blood cell count abnormal, Fatigue, Productive cough, Use of accessory respiratory muscles, Chest pain, Hypokinesia, Cough, Gait disturbance, Asthenia, Arthralgia, Pain, Myalgia, Inflammation, Decreased appetite, Back pain, Metastases to lung, Memory impairment, |
||||
FULVESTRANT, RIBOCICLIB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, FENTANYL CITRATE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, |
||||
| 1826 | 24852052 |
CA |
40 | 2 |
Abdominal discomfort, Abdominal distension, Abdominal pain upper, Adverse reaction, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Asthenia, Back injury, Blepharospasm, Blister, Blood cholesterol increased, Breast cancer stage III, Bursitis, C-reactive protein abnormal, C-reactive protein increased, Coeliac disease, Condition aggravated, Confusional state, Contraindicated product administered, Decreased appetite, Depression, Diarrhoea, Dizziness, Drug hypersensitivity, Drug ineffective, Drug intolerance, Drug-induced liver injury, Dry mouth, Duodenal ulcer perforation, Dyspepsia, Dyspnoea, Epilepsy, Exposure during pregnancy, Facet joint syndrome, Fall, Fatigue, Fibromyalgia, Finger deformity, Folliculitis, Gait inability, Gastrointestinal disorder, Gastrooesophageal reflux disease, General physical health deterioration, Glossodynia, Grip strength decreased, Hand deformity, Headache, Helicobacter infection, Hepatic enzyme increased, Hepatitis, Hypercholesterolaemia, Hypersensitivity, Hypertension, Hypoaesthesia, Ill-defined disorder, Impaired healing, Incorrect product administration duration, Inflammation, Infusion related reaction, Injection site reaction, Injury, Insomnia, Intentional product use issue, Irritable bowel syndrome, Joint range of motion decreased, Joint swelling, Lip dry, Live birth, Liver function test increased, Liver injury, Lower respiratory tract infection, Lung disorder, Malaise, Maternal exposure during pregnancy, Memory impairment, Migraine, Mobility decreased, Muscle injury, Muscle spasms, Muscular weakness, Musculoskeletal pain, Musculoskeletal stiffness, Nail disorder, Nasopharyngitis, Nausea, Neck pain, Night sweats, Obesity, Off label use, Onychomadesis, Onychomycosis, Osteoarthritis, Overdose, Pain, Pain in extremity, Paraesthesia, Pemphigus, Pericarditis, Peripheral swelling, Peripheral venous disease, Pneumonia, Product label confusion, Product quality issue, Product use in unapproved indication, Psoriatic arthropathy, Rash, Rheumatic fever, Rheumatoid arthritis, Sleep disorder, Stomatitis, Swelling, Synovitis, Systemic lupus erythematosus, Taste disorder, Therapeutic product effect decreased, Treatment failure, Type 2 diabetes mellitus, Underdose, Urticaria, Vomiting, Weight increased, Wheezing, Wound, Wound infection, |
||||
BUPRENORPHINE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN AND CODEINE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ALENDRONATE SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, ATOMOXETINE HYDROCHLORIDE, AZATHIOPRINE, BOTULINUM TOXIN TYPE A, CALCIUM CARBONATE, ANTACID, CANDESARTAN, CELECOXIB, CELECOXIB, CELECOXIB, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CORTISONE ACETATE, CORTISONE ACETATE, SECUKINUMAB, SECUKINUMAB, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ETANERCEPT, ETANERCEPT, ETANERCEPT, ERENUMAB-AOOE, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, GOLIMUMAB, GOLIMUMAB, ADALIMUMAB, LAMOTRIGINE, LAMOTRIGINE, LAMOTRIGINE, LAMOTRIGINE, LEFLUNOMIDE, LEFLUNOMIDE, MEPOLIZUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 1827 | 24852609 |
DE |
72 | 2 |
General physical health deterioration, Decreased appetite, Haematemesis, Large intestinal stenosis, Ileus, Pneumonia, Pneumonitis, C-reactive protein increased, General physical health deterioration, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 1828 | 24856012 |
78 | 2 | |
Diarrhoea, General physical health deterioration, |
||||
TIRZEPATIDE, |
||||
| 1829 | 24857017 |
60 | 1 | |
Disease complication, Renal transplant, Hypotension, Liver disorder, Renal disorder, Cardiac disorder, General physical health deterioration, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLIC ACID, MYCOPHENILIC ACID, |
||||
| 1830 | 24842131 |
CA |
40 | 2 |
Psoriatic arthropathy, Lung disorder, Pemphigus, Inflammation, Blepharospasm, Gait inability, Bursitis, Off label use, Coeliac disease, Lip dry, Vomiting, Hypercholesterolaemia, Gastrooesophageal reflux disease, Drug-induced liver injury, Synovitis, Glossodynia, Musculoskeletal pain, Blood cholesterol increased, Drug ineffective, Fall, Dyspnoea, Liver injury, Joint swelling, Anti-cyclic citrullinated peptide antibody positive, Headache, Abdominal discomfort, Alopecia, Product quality issue, Therapeutic product effect decreased, Exposure during pregnancy, Epilepsy, Blister, Drug intolerance, Night sweats, Breast cancer stage III, Onychomadesis, Hypertension, Hepatic enzyme increased, Wound, Stomatitis, Confusional state, Hepatitis, Lower respiratory tract infection, Product use in unapproved indication, Swelling, Finger deformity, Musculoskeletal stiffness, Nausea, Incorrect product administration duration, C-reactive protein abnormal, Fibromyalgia, Nasopharyngitis, Urticaria, Hypoaesthesia, General physical health deterioration, Nail disorder, Injury, Taste disorder, Peripheral venous disease, Fatigue, Drug hypersensitivity, Osteoarthritis, Dyspepsia, Gastrointestinal disorder, Dizziness, Peripheral swelling, Malaise, Insomnia, Muscular weakness, Obesity, Arthropathy, Rash, Rheumatoid arthritis, Pain, Abdominal distension, Condition aggravated, Impaired healing, Muscle injury, Duodenal ulcer perforation, Mobility decreased, Underdose, Ill-defined disorder, Contraindicated product administered, Neck pain, Intentional product use issue, Liver function test increased, Grip strength decreased, Overdose, Folliculitis, Abdominal pain upper, Systemic lupus erythematosus, Maternal exposure during pregnancy, Live birth, Wound infection, Memory impairment, Weight increased, Wheezing, Product label confusion, Injection site reaction, Diarrhoea, Pain in extremity, Sleep disorder, Type 2 diabetes mellitus, Pneumonia, Dry mouth, C-reactive protein increased, Muscle spasms, Arthralgia, Joint range of motion decreased, Facet joint syndrome, Paraesthesia, Rheumatic fever, Hand deformity, Treatment failure, Pericarditis, Back injury, Adverse reaction, Migraine, Hypersensitivity, Asthenia, Infusion related reaction, Decreased appetite, Irritable bowel syndrome, Depression, Helicobacter infection, Onychomycosis, Intentional product use issue, |
||||
TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, BUPRENORPHINE, GOLIMUMAB, GOLIMUMAB, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, LAMOTRIGINE, LAMOTRIGINE, LAMOTRIGINE, LAMOTRIGINE, ATOMOXETINE HYDROCHLORIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, SECUKINUMAB, SECUKINUMAB, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, CORTISONE ACETATE, CORTISONE ACETATE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, AZATHIOPRINE, ERENUMAB-AOOE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, CALCIUM CARBONATE, ANTACID, CALCIUM CARBONATE, ANTACID, CALCIUM CARBONATE, ANTACID, ETANERCEPT, ETANERCEPT, ETANERCEPT, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, MEPOLIZUMAB, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, CELECOXIB, CELECOXIB, CELECOXIB, BOTULINUM TOXIN TYPE A, CANDESARTAN, |
||||
| 1831 | 24842152 |
CA |
43 | 2 |
Abdominal discomfort, Blister, Autoimmune disorder, Arthropathy, Back injury, Confusional state, Dislocation of vertebra, Gastrointestinal disorder, Infection, Drug ineffective, Arthralgia, Dry mouth, Liver injury, C-reactive protein increased, Weight increased, Depression, Drug intolerance, Peripheral swelling, Wheezing, Infusion site reaction, Hypoaesthesia, Hypertension, Dyspnoea, Therapeutic product effect incomplete, Pain in extremity, Muscular weakness, Headache, Joint swelling, General physical health deterioration, Hand deformity, Neck pain, Asthenia, Synovitis, Nausea, Adverse drug reaction, Anxiety, Alopecia, Mobility decreased, Contusion, Hepatic enzyme increased, Blood cholesterol increased, Urticaria, Exposure during pregnancy, Adverse event, Glossodynia, Taste disorder, Swelling, Night sweats, Pericarditis, Maternal exposure during pregnancy, Off label use, Product quality issue, Injury, Fatigue, Asthma, Dizziness, Psoriatic arthropathy, Lower respiratory tract infection, Condition aggravated, Lip dry, Duodenal ulcer perforation, Abdominal pain upper, Rheumatoid arthritis, Blepharospasm, Abdominal pain, Paraesthesia, Osteoarthritis, Onychomadesis, Breast cancer stage III, Product use in unapproved indication, Live birth, Product use issue, Gastrooesophageal reflux disease, Nasopharyngitis, Type 2 diabetes mellitus, Drug hypersensitivity, Lung disorder, Musculoskeletal pain, Diarrhoea, Therapeutic product effect decreased, Nail disorder, Systemic lupus erythematosus, Infusion related reaction, Muscle spasms, Wound, Rash, Wound infection, Vomiting, Impaired healing, Muscle injury, Hypercholesterolaemia, Inflammation, Folliculitis, Contraindicated product administered, Obesity, Irritable bowel syndrome, Gait inability, Bursitis, Memory impairment, Treatment failure, Epilepsy, Peripheral venous disease, Pemphigus, Helicobacter infection, Facet joint syndrome, Deep vein thrombosis postoperative, Pain, Liver function test increased, Joint range of motion decreased, Anti-cyclic citrullinated peptide antibody positive, Decreased appetite, Migraine, Discomfort, Stomatitis, Intentional product use issue, C-reactive protein abnormal, Fibromyalgia, |
||||
LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, TRETINOIN, MEPOLIZUMAB, SECUKINUMAB, SECUKINUMAB, ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, LAMOTRIGINE, |
||||
| 1832 | 24842501 |
CA |
2 | |
Contraindicated product administered, Drug intolerance, Intentional product use issue, Maternal exposure during pregnancy, Medication error, Nasopharyngitis, Off label use, Pain, Pemphigus, Pericarditis, Peripheral swelling, Product use issue, Pyrexia, Rheumatoid arthritis, Sinusitis, Sleep disorder, Sleep disorder due to general medical condition, insomnia type, Stomatitis, Swelling, Synovitis, Wound, Systemic lupus erythematosus, Pruritus, Insomnia, Weight increased, Rash, Drug ineffective, Therapeutic product effect decreased, Treatment failure, Lower respiratory tract infection, Helicobacter infection, Alopecia, Abdominal discomfort, Arthropathy, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Blister, Condition aggravated, Confusional state, Contusion, Discomfort, Duodenal ulcer perforation, Dyspnoea, Fatigue, Folliculitis, Gastrointestinal disorder, General physical health deterioration, Glossodynia, Hand deformity, Hepatic enzyme increased, Hypersensitivity, Ill-defined disorder, Impaired healing, Infection, Infusion related reaction, Injury, Irritable bowel syndrome, Joint swelling, Muscle injury, |
||||
CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, TOCILIZUMAB, ALENDRONATE SODIUM, APREPITANT, LEFLUNOMIDE, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CORTISONE ACETATE, HYDROCORTISONE ACETATE, DESOXIMETASONE, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ETANERCEPT, FOLIC ACID, ALENDRONATE SODIUM, ADALIMUMAB, HYDROXYCHLOROQUINE, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, ABATACEPT, OXYCODONE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, INFLIXIMAB, RITUXIMAB, GOLIMUMAB, USTEKINUMAB, TOCILIZUMAB, USTEKINUMAB, TOFACITINIB, SULFASALAZINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ACETAMINOPHEN AND CODEINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, PANTOPRAZOLE, DEXAMETHASONE SODIUM PHOSPHATE, |
||||
| 1833 | 24842926 |
PA |
1 | |
General physical health deterioration, Aphasia, Terminal state, Prostate cancer metastatic, Cerebral infarction, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 1834 | 24842958 |
US |
||
General physical health deterioration, |
||||
| 1835 | 24843129 |
FR |
29 | 1 |
Sarcoid-like reaction, Pyrexia, Inflammation, Neck pain, Decreased appetite, General physical health deterioration, Sweating fever, Oedema peripheral, Skin lesion, Erythema, Inflammation, Cough, Dyspnoea, Sarcoidosis, Dizziness, Myalgia, Headache, Arthralgia, |
||||
DUPILUMAB, IVERMECTIN, |
||||
| 1836 | 24843217 |
SI |
1 | |
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1837 | 24843346 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1838 | 24843399 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1839 | 24843415 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1840 | 24843416 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1841 | 24843444 |
US |
69 | 2 |
General physical health deterioration, Injection site thrombosis, Dyspnoea, Haematochezia, Blood magnesium decreased, Blood potassium decreased, Weight increased, Cough, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, MIDODRINE HYDROCHLORIDE, FAMOTIDINE, RIOCIGUAT, LORAZEPAM, ESOMEPRAZOLE MAGNESIUM, DROXIDOPA, OXYGEN, 0XYGEN, PREDNISONE, CYPROHEPTADINE HYDROCHLORIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MIRTAZAPINE, APIXABAN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 1842 | 24843494 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1843 | 24843497 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1844 | 24843516 |
CA |
72 | 1 |
Acute myeloid leukaemia, Confusional state, Enterococcal sepsis, Febrile neutropenia, General physical health deterioration, Klebsiella sepsis, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, MEROPENEM, VANCOMYCIN HYDROCHLORIDE, |
||||
| 1845 | 24843565 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1846 | 24843761 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1847 | 24843813 |
US |
1 | |
Death, General physical health deterioration, Off label use, |
||||
METRELEPTIN, LISINOPRIL, SERTRALINE HYDROCHLORIDE, VALSARTAN, ERGOCALCIFEROL, FUROSEMIDE, CARVEDILOL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, INSULIN HUMAN, MAGNESIUM, |
||||
| 1848 | 24843819 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1849 | 24843941 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1850 | 24843942 |
US |
||
General physical health deterioration, Platelet count decreased, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1851 | 24844279 |
US |
52 | 2 |
Emotional distress, General physical health deterioration, Rash, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1852 | 24844584 |
CA |
82 | 1 |
General physical health deterioration, Dysuria, Burns second degree, |
||||
DUPILUMAB, DUPILUMAB, PREDNISONE, |
||||
| 1853 | 24844860 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1854 | 24844872 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1855 | 24844884 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1856 | 24844983 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1857 | 24845009 |
AT |
57 | 1 |
Therapeutic product effect incomplete, Amyloidosis, Quadriplegia, General physical health deterioration, Hypertension, Off label use, |
||||
DARATUMUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CARFILZOMIB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 1858 | 24845116 |
US |
||
General physical health deterioration, |
||||
OCRELIZUMAB, |
||||
| 1859 | 24845874 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1860 | 24845882 |
DE |
2 | |
Pleural effusion, Dyspnoea, Blood urea increased, Blood uric acid increased, Blood creatinine increased, Alanine aminotransferase increased, Aspartate aminotransferase increased, Abdominal wall abscess, Impaired healing, Enterocutaneous fistula, Metastases to peritoneum, Vomiting, Abdominal pain, Ascites, Dyspnoea, Fistula, Malignant neoplasm progression, Breast cancer metastatic, Nausea, Aspiration pleural cavity, Nausea, Dental caries, Diarrhoea, Dental caries, Vomiting, Diarrhoea, Anaemia, General physical health deterioration, Weight decreased, |
||||
FULVESTRANT, RIBOCICLIB, |
||||
| 1861 | 24845898 |
US |
||
General physical health deterioration, Malaise, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1862 | 24845931 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1863 | 24846064 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1864 | 24846140 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1865 | 24846193 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1866 | 24846281 |
CA |
1 | |
Crohn^s disease, Choking, Prostate cancer metastatic, General physical health deterioration, Visual impairment, Movement disorder, Emphysema, Joint swelling, Poor quality sleep, Osteoarthritis, Fatigue, Anxiety, |
||||
ADALIMUMAB-ADAZ, METHOTREXATE, METHOTREXATE SODIUM, SULFASALAZINE, |
||||
| 1867 | 24846412 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1868 | 24846686 |
CA |
2 | 1 |
Blood glucose abnormal, Blood pressure decreased, Dyspnoea, General physical health deterioration, Hypervolaemia, Hypotension, Listless, Respiratory distress, Somnolence, |
||||
SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SOTALOL HYDROCHLORIDE, |
||||
| 1869 | 24846803 |
JP |
75 | 1 |
Multiple organ dysfunction syndrome, General physical health deterioration, Chronic myeloid leukaemia, |
||||
LENALIDOMIDE, |
||||
| 1870 | 24846811 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1871 | 24846848 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1872 | 24846907 |
TR |
68 | 1 |
General physical health deterioration, Decubitus ulcer, C-reactive protein increased, |
||||
| 1873 | 24846986 |
US |
65 | 2 |
Rheumatoid arthritis, General physical health deterioration, |
||||
ABATACEPT, ABATACEPT, ABATACEPT, |
||||
| 1874 | 24847034 |
FR |
72 | 2 |
General physical health deterioration, |
||||
| 1875 | 24847052 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1876 | 24838845 |
CA |
64 | 2 |
Nausea, General physical health deterioration, Areflexia, Blood albumin abnormal, Diarrhoea, Escherichia bacteraemia, Hypophosphataemia, Motor dysfunction, Physical deconditioning, Similar reaction on previous exposure to drug, Myalgia, Arthralgia, Asthenia, Hypocalcaemia, |
||||
| 1877 | 24838941 |
HU |
75 | 1 |
Death, Abdominal pain, Diarrhoea, General physical health deterioration, |
||||
QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, MEMANTINE, MEMANTINE HYDROCHLORIDE, QUETIAPINE FUMARATE, QUETIAPINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 1878 | 24839075 |
US |
24 | 2 |
Disseminated intravascular coagulation, Septic shock, General physical health deterioration, Off label use, |
||||
GANCICLOVIR SODIUM, GANCICLOVIR, BORTEZOMIB FOR INJECTION, BORTEZOMIB, ALEMTUZUMAB, |
||||
| 1879 | 24839452 |
FR |
||
General physical health deterioration, Hyperthermia, Device related infection, Bronchitis, Pneumonia, |
||||
BEVACIZUMAB, PACLITAXEL, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, |
||||
| 1880 | 24839501 |
CA |
||
Contraindicated product administered, Lower respiratory tract infection, Helicobacter infection, Drug intolerance, Intentional product use issue, Maternal exposure during pregnancy, Medication error, Nasopharyngitis, Off label use, Pain, Pemphigus, Pericarditis, Peripheral swelling, Product use issue, Pyrexia, Rheumatoid arthritis, Sinusitis, Sleep disorder, Sleep disorder due to general medical condition, insomnia type, Stomatitis, Swelling, Synovitis, Wound, Systemic lupus erythematosus, Rash, Pruritus, Insomnia, Weight increased, Drug ineffective, Therapeutic product effect decreased, Treatment failure, Alopecia, Abdominal discomfort, Arthropathy, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Blister, Condition aggravated, Confusional state, Contusion, Discomfort, Duodenal ulcer perforation, Dyspnoea, Fatigue, Folliculitis, Gastrointestinal disorder, General physical health deterioration, Glossodynia, Hand deformity, Hepatic enzyme increased, Hypersensitivity, Ill-defined disorder, Impaired healing, Infection, Infusion related reaction, Injury, Irritable bowel syndrome, Joint swelling, Muscle injury, |
||||
CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 1881 | 24839674 |
CA |
2 | 1 |
Blood glucose abnormal, Blood pressure decreased, Dyspnoea, General physical health deterioration, Hypervolaemia, Hypotension, Listless, Oxygen therapy, Respiratory distress, Somnolence, |
||||
SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SOTALOL HYDROCHLORIDE, |
||||
| 1882 | 24840214 |
CA |
||
General physical health deterioration, Intentional product use issue, |
||||
USTEKINUMAB-STBA, |
||||
| 1883 | 24840435 |
DE |
69 | 1 |
General physical health deterioration, |
||||
| 1884 | 24840759 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1885 | 24840770 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1886 | 24840903 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1887 | 24840913 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1888 | 24840943 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1889 | 24840944 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1890 | 24840982 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1891 | 24840990 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1892 | 24840995 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1893 | 24841040 |
US |
78 | 1 |
Prostate cancer, General physical health deterioration, Prostatic specific antigen increased, Fatigue, Malignant neoplasm progression, Haemoglobin decreased, Dyspnoea, Gait disturbance, Arthralgia, Bone pain, Pyrexia, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, IRON, DENOSUMAB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ENZALUTAMIDE, GABAPENTIN, GEMFIBROZIL, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METOPROLOL TARTRATE, METOPROLOL, OXYCODONE, POLYETHYLENE GLYCOL, SEMAGLUTIDE, SENNOSIDES, SENNA LEAF, SENNA, SENNOSIDES 8.6 MG TABLETS, TERAZOSIN, TERAZOSIN HYDROCHLORIDE, CALCIUM, ERGOCALCIFEROL, DEXTROSE MONOHYDRATE, DEXTROSE, DIPHENHYDRAMINE HYDROCHLORIDE, DOCUSATE SODIUM, DOCUSATE SODIUM - SENNOSIDES, ENOXAPARIN SODIUM, DEXTROSE MONOHYDRATE, DEXTROSE, INSULIN LISPRO, LABETALOL, MELATONIN, NALOXONE HYDROCHLORIDE NASAL, NALOXONE HYDROCHLORIDE, PHENOL, POLYETHYLENE GLYCOL 3350, PROMETHAZINE HYDROCHLORIDE, REMDESIVIR, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, PREDNISONE, SEMAGLUTIDE, |
||||
| 1894 | 24841050 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1895 | 24841051 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1896 | 24841255 |
US |
69 | |
Kidney infection, General physical health deterioration, Fluid retention, |
||||
DAPAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN, SACUBITRIL AND VALSARTAN, SACUBITRIL AND VALSARTAN, |
||||
| 1897 | 24841282 |
CA |
85 | 2 |
Ecchymosis, Fall, General physical health deterioration, Pancytopenia, Petechiae, Physical deconditioning, |
||||
PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, NITROFURANTOIN, NITROFURANTOIN MONOHYDRATE/MACROCRYSTALS, NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), DONEPEZIL HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 1898 | 24841518 |
US |
49 | 2 |
Oxygen saturation decreased, General physical health deterioration, Abdominal pain, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 1899 | 24841547 |
SE |
55 | 2 |
Pyrexia, Rash, Hepatic enzyme increased, General physical health deterioration, |
||||
PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, |
||||
| 1900 | 24841620 |
BG |
78 | 2 |
Neutropenia, Second primary malignancy, Gastric cancer, General physical health deterioration, Weight decreased, |
||||
PALBOCICLIB, PALBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28